In a nutshell
This study assessed the safety and effectiveness of a new formulation of exenatide compared to sitaglipitin in patients with sub-optimal blood sugar control taking metformin.
This study concluded that exenatide reduced blood sugar levels over 3 months more effectively than sitaglipitin.
There are many blood glucose-lowering medications available for the treatment of diabetes. Metformin is the first-line treatment for type 2 diabetes. It is often prescribed in combination with other glucose-lowering medications. One type of medication targets a receptor called glucagon-like peptide receptor or GLP-1r. Exenatide and sitagliptin are two such medications. Exenatide activates GLP-1r and sitagliptin enhances activity of GLP-1r.
Exenatide has been shown to be more effective than sitagliptin at reducing blood sugar when administered once weekly using a dual-chamber pen. Exenatide is now available in a suspension form, at the same dose, which makes it easier to administer. Ease of use is important and can impact how well the patient manages blood glucose.
Methods & findings
The safety and effectiveness of the new formulation of exenatide is investigated in this study.
311 patients with type 2 diabetes were included in this study. Patients were randomly assigned to receive either exenatide once-weekly suspension for autoinjection (QWS-AI), sitagliptin, or placebo (substance with no active effect) while maintaining standard metformin therapy. Assessment was performed at the end of a 28-week period.
Exenatide QWS-AI reduced HbA1c levels (average blood glucose over 3 months) more than sitagliptin or placebo. More patients receiving exenatide QWS-AI achieved an HbA1c level less than 7% (43.1% exenatide versus 32% sitagliptin).
Body weight decreased with both exenatide QWS-AI and sitagliptin. Side effects were reported by 55.8% of patients receiving exenatide QWS-AI, compared to 32.8% of sitagliptin and 47.5% of placebo patients. The most common side effects associated with exenatide QWS-AI were gastrointestinal (nausea, diarrhea, vomiting) and injection-site reactions.
The bottom line
This study concluded that exenatide QWS-AI is more effective than sitagliptin in reducing blood sugar levels in combination with standard metformin therapy.
Managing blood glucose levels is important for managing type 2 diabetes. Please discuss this with your doctor if you have any concerns.
Published By :
Diabetes, Obesity and Metabolism
Feb 16, 2017
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?